Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
Myung‐Ju Ahn(Sungkyunkwan University), Jaafar Bennouna(Hôpital Foch), Óscar Juan(Hospital Universitari i Politècnic La Fe), Elvire Pons‐Tostivint(Centre Hospitalier Universitaire de Nantes), Min Hee Hong(Yonsei University), Gaëtan Catala, Paul Howarth(Daiichi Sankyo (United States)), Céline Mascaux(Hôpitaux Universitaires de Strasbourg), Michael Chargualaf(Daiichi Sankyo (United States)), Manuel Cobo(Instituto de Investigación Biomédica de Málaga), Naveen S. Basappa, Yu Yao(Fudan University), Hidetoshi Hayashi(Kindai University), M. Pérol(Centre Léon Bérard), Sebahat Ocak(CHU Dinant Godinne UCL Namur), Robin Cornelissen(Erasmus MC Cancer Institute), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Elena Poddubskaya, Jacob Sands(Harvard University), Satoru Kitazono(The Cancer Institute Hospital), Daniel Brungs(University of Wollongong), Christos S. Karapetis(Clínica Alemana), Deise Uema(Daiichi Sankyo (United States)), Richard D. Hall(University of Virginia Health System), Aaron Lisberg(APLA Health), Shunichi Sugawara(Sendai Kousei Hospital), Sagun Parakh(Australian Research Council), Gastón Lucas Martinengo(Chinese Academy of Medical Sciences & Peking Union Medical College), Cheol Park(Global College), Ines B. Menjak, Milada Zemanová, Enriqueta Felip(Institut Català d'Ornitologia), Nicolas Girard(Institut Curie), Marina Chiara Garassino(University of Chicago), Adnan Nagria, Yong Zhang(Daiichi Sankyo (United States)), Jialei Wang(Huaian First People’s Hospital), Geoffrey Liu(Princess Margaret Cancer Centre), Kentaro Tanaka(Institute for the Future), Hongmei Sun, Bo Gao, Feng Luo(Guiyang College of Traditional Chinese Medicine), Frédéric Forget, Juan Puig(Hospital Universitario La Paz), Shun Lü(Shanghai Jiao Tong University), David Vicente Baz(Hospital Universitario Virgen Macarena), Benjamin Shieh
Cited by 177
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k